We could not find any results for:
Make sure your spelling is correct or try broadening your search.
euticals Inc - Westchester, New York-based pharmaceutical company - Says it expects second quarter 2024 earnings calcu ...
The EU has approved Sanofi's blockbuster drug Dupixent for the treatment of chronic obstructive pulmonary disease (CO ...
Sanofi SA and Regeneron Pharmaceuticals Inc on Thursday said the US Food & Drug Administration approved Dupixent as t ...
A number of leading pharmaceutical companies on Monday reported positive trial results on the treatment of lymphoma, ...
A Regeneron Pharmaceuticals Inc and Sanofi Inc new drug therapy to treat moderate to severe eczema in young children ...
Regeneron Pharmaceuticals Inc soared on Thursday after saying two trials investigating aflibercept given at a higher ...
Sanofi SA on Thursday said it has agreed to assign worldwide exclusive rights to cancer drug Libtayo to partner Regen ...
Regeneron Pharmaceuticals Inc, a New York-based biotechnology firm, and Paris-based Sanofi SA announced on Tuesday th ...
-based healthcare company - and Regeneron Pharmaceuticals Inc - New York-based biotechnology company - Say detailed po ...
Sanofi SA and Regeneron Pharmaceuticals Inc said on Saturday that in a phase 3 trial of its monoclonal antibody Dupix ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 296.6 | 296.6 | 296.6 | 1173 | 296.6 | DE |
4 | 0 | 0 | 296.6 | 296.6 | 296.6 | 1929 | 296.6 | DE |
12 | 0 | 0 | 296.6 | 296.6 | 296.6 | 965 | 296.6 | DE |
26 | 0 | 0 | 296.6 | 296.6 | 296.6 | 1317 | 296.6 | DE |
52 | 0 | 0 | 296.6 | 296.6 | 296.6 | 1248 | 296.6 | DE |
156 | 0 | 0 | 296.6 | 296.6 | 296.6 | 1989 | 296.6 | DE |
260 | 0 | 0 | 296.6 | 296.6 | 296.6 | 1454 | 296.6 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions